US · biotechnology · gene therapy
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series A · May 2026 · $97M
8VC lead, DCVC Bio lead, CHOP
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.